Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features. | Am J Surg Pathol | 2026 | 42252958 | PubTator, text mining | PubMed |
| Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025). | Front Oncol | 2026 | 42245686 | PubTator, text mining | PubMed |
| Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer. | medRxiv | 2026 | 42245046 | PubTator, text mining | PubMed |
| Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure. | Gynecol Oncol | 2026 | 42235136 | PubTator, text mining | PubMed |
| Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models. | Sci Transl Med | 2026 | 42234772 | PubTator, text mining | PubMed |
| Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma. | Br J Cancer | 2026 | 42231029 | PubTator, text mining | PubMed |
| Advanced radiotherapy and systemic therapy in head and neck adenoid cystic carcinoma: Current progress and future integrated strategies. | Transl Oncol | 2026 | 42229289 | PubTator, text mining | PubMed |
| B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer. | Endocr Relat Cancer | 2026 | 42227355 | PubTator, text mining | PubMed |
| Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going? | Cancer | 2026 | 42226007 | PubTator, text mining | PubMed |
| Emerging role of antibody-drug conjugates in gastrointestinal malignancies. | Cancer | 2026 | 42225890 | PubTator, text mining | PubMed |
| Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. | J Clin Oncol | 2026 | 42218654 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions. | Future Oncol | 2026 | 42200370 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions. | Biomolecules | 2026 | 42194027 | PubTator, text mining | PubMed |
| Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2026 | 42192993 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan for endocrine-resistant HR-positive/HER2-negative breast cancer: biological rationale and clinical evidence. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42183859 | PubTator, text mining | PubMed |
| Non-competing Trop2 nanobody-based radiotheranostics for precision imaging and therapy of pancreatic cancer. | Mater Today Bio | 2026 | 42182874 | PubTator, text mining | PubMed |
| Antibody-drug conjugates for primary brain tumors. | Front Oncol | 2026 | 42180101 | PubTator, text mining | PubMed |
| High TROP-2 expression as a predictor of poor neoadjuvant chemotherapy response in luminal B breast cancer: a retrospective clinicopathological study. | BMC Cancer | 2026 | 42177446 | PubTator, text mining | PubMed |
| Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity. | Sci Adv | 2026 | 42172336 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study. | Transl Breast Cancer Res | 2026 | 42170579 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=8